Please try another search
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
Name | Age | Since | Title |
---|---|---|---|
Paul J. Sekhri | 66 | 2020 | Independent Chairman of the Board |
Kevin R. Lind | 48 | 2020 | President, CEO, Secretary & Director |
Vincent E. Aurentz | 56 | 2020 | Independent Director |
Phillip M. Schneider | 68 | 2020 | Independent Director |
Corinne M. Le Goff | 59 | 2021 | Independent Director |
Casey C. Lynch | 50 | 2021 | Independent Director |
Jane Tiller | 60 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review